

Title	Deuterated Alkyl Sulfonium Salt Reagents; Importance of H/D Exchange Methods in Drug Discovery
Author(s)	Ogasahara, Riku; Ban, Kazuho; Mae, Miyu et al.
Citation	ChemMedChem. 2024
Version Type	VoR
URL	https://hdl.handle.net/11094/97148
rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
Note	

Osaka University Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

Osaka University

Deuterated Alkyl Sulfonium Salt Reagents; Importance of H/D Exchange Methods in Drug Discovery

Riku Ogasahara,^[a] Kazuho Ban,^[a] Miyu Mae,^[a] Shuji Akai,^[a] and Yoshinari Sawama^{*[a, b]}

Deuterated drugs (heavy drugs) have recently been spotlighted as a new modality for small-molecule drugs because the pharmacokinetics of pharmaceutical drugs can be enhanced by replacing C–H bonds with more stable C–D bonds at metabolic positions. Therefore, deuteration methods for drug candidates are a hot topic in medicinal chemistry. Among them, the H/D exchange reaction (direct transformation of C–H bonds to C–D bonds) is a useful and straightforward method for creating novel deuterated target molecules, and over 20 reviews on the synthetic methods related to H/D exchange reactions have been published in recent years. Although various deuterated

drug candidates undergo clinical trials, approved deuterated drugs possess CD₃ groups in the same molecule. However, less diversification, except for the CD₃ group, is a problem for future medicinal chemistry. Recently, we developed various deuterated alkyl (*d_n*-alkyl) sulfonium salts based on the H/D exchange reaction of the corresponding hydrogen form using D₂O as an inexpensive deuterium source to introduce CD₃, CH₃CD₂, and ArCH₂CD₂ groups into drug candidates. This concept summarises recent reviews related to H/D exchange reactions and novel reagents that introduce the CD₃ group, and our newly developed electrophilic *d_n*-alkyl reagents are discussed.

Introduction

Deuterium (D) is a nonradioactive and stable isotope of hydrogen (H). Compounds containing deuterium are widely used in various drug discoveries^[1] and studies to elucidate life phenomena (live-cell Raman imaging,^[2] metabolic imaging using magnetic resonance imaging,^[3] and mass analysis).^[4,5] Among these, deuterated drugs (heavy drugs)^[1] have recently attracted considerable attention owing to the significant deuterium kinetic isotope effect (KIE) arising from the higher dissociation energy of the carbon–deuterium (C–D) bond compared with that of carbon–hydrogen (C–H) bond. Many pharmaceutical drugs undergo cytochrome P450 (CYP)-mediated oxidative metabolism, and the replacement of C–H bonds with more stable C–D bonds at their metabolic sites, especially at the α -position of heteroatoms, can improve their pharmacokinetics. For example, tetrabenazine (Figure 1; hydrogen form bearing no deuterium atom) is used to treat chorea in Huntington's disease, and its 9- and 10-dimethoxy (OCH₃) groups undergo CYP-mediated metabolism to reduce its bioactivity. In contrast, the *deuterium-switch* deutetrabenazine, possessing 9- and 10-di-(*d*₃-methoxy) (–OCD₃) groups, acquires




Figure 1. Approved heavy drugs.

stronger metabolic tolerance and was approved as the first deuterated drug by the US Food and Drug Administration in 2017.^[1c] Furthermore, deucravacitinib, a *de novo* heavy drug, was approved for treating plaque psoriasis in 2022.^[1g]

Considering deuterium's usefulness in various applications, including deuterated drugs, the development of various deuteration methods has recently gained momentum. Traditionally, deuterium introduction with skeleton transformation using reductants (LiAlD₄/NaBD₄/D₂O) and reactive deuterium sources (CD₂O/CD₃I) has been adopted to construct deuterated drug candidates.^[6] In contrast, H/D exchange reactions (direct conversion of C–H bonds to C–D bonds) can be powerful tools for targeting deuterated molecules. Various H/D exchange methods using acids, bases, metal catalysts, or photocatalysts have been developed and summarized in review articles (Table 1).^[7–26] D₂O, CD₃OD, DMSO-*d*₆, D₂, C₆D₆ etc., were utilized as the deuterium sources in each reaction, and using D₂O as an abundant and inexpensive deuterium source was considered ideal.

[a] R. Ogasahara, K. Ban, M. Mae, Prof. Dr. S. Akai, Dr. Y. Sawama
Graduate School of Pharmaceutical Sciences
Osaka University
1-6 Yamada-oka, Suita, Osaka 565-0871, Japan
E-mail: sawama@phs.osaka-u.ac.jp

[b] Dr. Y. Sawama
Deuterium Science Research Unit, Center for the Promotion of Interdisciplinary Education and Research
Kyoto University, Yoshida, Sakyo-ku, Kyoto 606-8501 (Japan)

© 2024 The Authors. ChemMedChem published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.


Although various deuterated drug candidates are undergoing clinical trials,^[15f] approved deuterated drugs till now possess CD₃ groups in the same molecule (Figure 1). These compounds were synthesized from commercially available CD₃OD, CD₃I, (CD₃)₂SO₄, CD₃NH₂ and so on. Additionally, recently developed CD₃ (*d*₃-methyl)-linked sulfonium salts are useful tools for introducing CD₃ groups into drug candidates. However, the high costs derived from commercially available deuterated reagents and less diversification, except for the CD₃ group, are problematic for future medicinal chemistry. Recently, we developed various deuterated alkyl (*d*_n-alkyl) sulfonium salts based on the H/D exchange reaction of the corresponding hydrogen form using D₂O as an inexpensive deuterium source to introduce CD₃, CH₃CD₂, and ArCH₂CD₂ groups into drug candidates. Therefore, these novel introduction methods for the CD₃ group were considered in detail, and the utility of the developed deuterated alkyl (*d*_n-alkyl) sulfonium salts is described below.

*d*₃-Methyl Sulfonium Salt Reagents^[27,28]

Wang and Zhao developed an electrophilic *d*₃-methylation reagent (1) from CD₃OD and dibenzothiophene (Figure 2-I).^[27] The reaction of CD₃OD with HCO₂H under acidic conditions gave *d*₃-methyl formate (HCO₂CD₃), which was then treated with dibenzothiophene and trifluoromethanesulfonic anhydride (Tf₂O) to afford *d*₃-methyl dibenzothiophenium salt (1) as *d*₃-methylation reagent with 99%D contents. 1 was efficiently reacted with various nucleophilic heteroatoms within the pharmaceutical drugs (ezetimibe, sulfamethoxazole, and spongouridine) and their related compounds (Cleland's reagent) to form the corresponding *d*₃-methylated products without any loss of D contents (Figure 2-II). Additionally, the substitution switch from the CH₃ group of methoxsalen to the CD₃ group was accomplished by demethylation using BBr₃ and subsequent *d*₃-methylation using 1.

Meng and Tan also developed a *d*₃-methylation reagent (2) consisting of a diaryl sulfonium salt (Figure 3-I).^[28] 2 was prepared from the corresponding *d*₃-methyl *p*-methyl(phenyl) sulfoxide using Tf₂O and electron-sufficient 1,3,5-trimethoxybenzene. Although the preparation method for *d*₃-methyl *p*-

(I) Preparation of *d*₃-methylation reagent (1).



(II) Introduction of *d*₃-methyl group using 1.





Figure 2. *d*₃-Methyl dibenzothiophenium salt reagent (Wang and Zhao's method). Tf₂O; trifluoromethanesulfonic anhydride.

(I) Preparation of *d*₃-methylation reagent (2).



(II) Introduction of *d*₃-methyl group using 2.




Figure 3. *d*₃-Methyl bis-aryl sulfonium salt reagent (Meng and Tan's method). DCE; 1,2-dichloroethane.

methyl(phenyl) sulfoxide has not been described in the literature, it can be assumed to be constructed by *d*₃-methylation of *p*-methylbenzenethiol using CD₃I and subsequent oxidation of the sulfur atom. Furthermore, *d*₃-methylated products were synthesized from ezetimibe, paracetamol, sulfamethazine, and fluoxetine using 2 as the electrophilic *d*₃-methylation reagent, and *d*₃-caffeine was also prepared.



Yoshinari Sawama received a B.Sc. degree from the faculty of pharmaceutical sciences at Osaka University in 2001. He obtained his Ph.D. degree at Osaka University in 2006 under the supervision of Professor Yasuyuki Kita. After working as a postdoctoral fellow at Osaka University (2006–2007), Dortmund Technical University (2007–2009) and Ritsumeikan University (2009–2010), he was appointed as an Assistant Professor at Gifu Pharmaceutical University in 2010. He was promoted to Lecturer in 2015 and Associate Professor at the same university in 2017. In 2021, he moved to Osaka University as an Associate Professor.

Table 1. Reviews for H/D exchange methods in 2015–2024.

Reference	Year	method (catalysts and reagents)	representative targets
[7]	2015	acids.	aromatic moiety of lignans.
[8]	2018	metal oxides, metal films.	alkanes.
[9]	2018	acids/bases, Pt, Ru, Pd, Rh, Ir, and Fe catalysts.	aromatics, alkenes, alkyl amines, alkyl alcohols, amino acids, olefins, hydrosilanes, hydroboranes.
[10]	2018	platinum group metal on carbons.	aromatics, benzylic positions, alkanes, sugars, saturated fatty acids
[11]	2019	Fe, Ni, and Co metals.	aromatics, benzylic positions.
[12]	2019	Ru, Ni, Mo, Mn, Fe, Ir, Pt, and base catalysts.	adjacent to heteroatoms (O, N, and S).
[13] ^[a]	2020	photocatalysts (Ir catalyst, 4CzIPN, TBADT and acridinium salt).	alkyl amines, hydrosilanes, aldehydes.
[14]	2020	acids/bases, Pd, Pt, Ru, Ir, Co, Mn, and Fe catalysts, photocatalyst (4CzIPN).	aromatics, benzylic positions, alkanes, alkyl amines, alkyl alcohol, sugars, amino acids, peptides, alkyl sulfides.
[15]	2020	Ir, Ru, Rh, Pt, and Pd catalysts.	aromatics, olefins, terminal alkynes.
[16]	2021	Ru, and Ir catalysts.	alkyl amines, aromatics, nucleotides, amino acids, peptides, alkyl sulfides, alkyl alcohols.
[17] ^[a]	2021	photocatalysts (4CzIPN, Ir catalysts, acridinium salt, and TBADT).	alkyl amines, amino acids, peptides, aldehydes, hydrosilanes.
[18]	2021	bases/acids, Ru, Ni, Pd, Ir, and Pt catalysts.	alkyl ketone, amino acids, peptides, alkyl alcohols, sugars, aromatics, benzylic positions, alkyl amines, alkyl sulfides.
[19] ^[a]	2021	Ru, Ir, and Pt catalysts, acids/bases.	alkyl cyanide, alkyl ketones, terminal alkyne, aromatics, alkyl alcohols, olefins, hydrosilanes.
[20] ^[a]	2022	photocatalysts (TBADT, 4CzIPN and Ir catalyst).	alkyl amines, peptides, aldehydes, hydrosilanes.
[21] ^[a]	2022	Ir, and Ru catalysts, photocatalysts (TBADT and 4CzIPN), NHCs.	aldehydes.
[22] ^[a]	2022	NHCs, photocatalysts (TBADT and 4CzIPN), Ir, Ru catalyst	aldehydes.
[6] ^[a]	2022	Pd, Pt, Rh, Ru, Ir, Ni, Mn, Co, Fe, and Ag catalysts, photocatalysts (4CzIPN, and Ir catalysts), acids/bases, NHCs.	aromatics, olefins, terminal alkynes, alkyl alcohols, alkyl sulfides, alkyl amines, amino acids, alkyl cyanides, allylic positions, benzylic positions, aldehydes, carbonyl (α position).
[23] ^[a]	2022	Ir, Pd, Rh, Ru, Ni, Cu, Fe, Ag, Co, and Mn catalysts, acids/bases, NHCs, AIBN, photocatalysts (4CzIPN, Ir catalyst, acridinium salt, and TBADT).	aromatics, olefins, terminal alkynes, alkyl amines, alkyl amides, amino acids, peptide, alkyl sulfides, benzylic positions, alkyl alcohols, nitromethane, saturated fatty acids, sugars, nucleotides (aromatics), aldehydes, carbonyl (α position).
[24]	2023	bases.	aromatics, benzylic positions, olefins, anisole, Si-CH ₃ .
[25] ^[a]	2023	acids/bases, Fe, Co, Rh, and Ru catalysts, photocatalyst (Ir catalyst), protein.	aromatics, olefins, benzylic positions, amino acids, aliphatic carboxylic acid, NHCs.
[26] ^[a]	2024	Ru, and Ir catalysts, photocatalyst (3DPA2FBN and 4CzIPN), AIBN.	alkyl amines, aromatics, amino acids.

[a] Other deuteration methods were also described, such as hydrogen/halogen exchange, reductive deuteration, deuteration via radical reaction intermediates, etc.; 4CzIPN: 1,2,3,5-Tetrakis(carbazol-9-yl)-4,6-dicyanobenzene, TBADT: tetrabutylammonium decatungstate, NHCs; *N*-heterocyclic carbenes, AIBN; azobis(isobutyronitrile), 3DPA2FBN; 2,4,6-Tris(diphenylamino)-3,5-difluorobenzonitrile.

Although the products possessed outstanding D contents, a slight loss of D contents arising from an undesirable D/H exchange reaction during the d_3 -methylation process was observed in some cases.

These two methods efficiently introduce d_3 -methyl group into pharmaceutical drugs and bioactive compounds. However, expensive CD₃ sources, such as CD₃OD and CD₃I, are required. Therefore, it is crucial to prepare a CD₃ source from inexpensive and abundant D₂O by the H/D exchange reaction and diversify the deuterated alkyl reagents, enabling the introduction of a limited number of deuterium atoms at the required positions (neighbouring positions at heteroatom; CYP-mediated metabolite positions).

Deuterated Alkyl Sulfonium Salt Reagents (Our Work)^[29]

Recently, we developed various deuterated alkyl (d_n -alkyl) diphenylsulfonium salts (**3**) based on the H/D exchange reaction of the corresponding hydrogen forms using D₂O as an inexpensive deuterium source, to introduce d_n -alkyl moieties into drug candidates (Figure 4).^[29] Hydrogen forms (alkyl sulfonium salts) were easily prepared by the coupling of diphenylsulfide with alkyl triflate or alkyl iodide, and converted to **3** with excellent D contents and perfect site-selectivity under basic conditions using K₂CO₃ and D₂O (Figure 4-I; alkyl dibenzosulfonium salt, such as **1** in Figure 2, was an inadequate substrate, and underwent hydrolysis to decompose the struc-



(I) Preparation of d_n -alkylation reagents (**3**).(II) Introduction of d_n -alkyl group using **3**.

Figure 4. Deuterated alkyl diphenylsulfonium salt reagents. DMF; *N,N*-dimethylformamide, THF; tetrahydrofuran, SM; starting material, brsm; based on recovered starting material.

ture). Consequently, d_3 -methyl-(**3a**) as well as d_2 -ethyl-(**3b**), d_2 -phenethyl-(**3c**), d_2 -*p*-methoxyphenethyl-(**3d**), d_2 -*p*-bromophenethyl-(**3e**), and d_2 -bromomethyl-(**3f**) substituted sulfonium salts were successfully prepared. **3** was then utilized as an electrophilic d_n -alkylating reagent (**3**) for various heteroatom-containing nucleophiles and 1,3-diketone substrate under the two reaction conditions (Figure 4-II, Procedures A and B). *N*-methyl-*N*- d_3 -methyl sulfonamide **5a** with excellent D contents was obtained from *N*-methylsulfonamide by successive addition of NaH, D_2O , and **3a** in THF (Procedure A: the reaction without D_2O led to the loss of D contents during d_3 -methylation step).

Alternatively, d_n -alkyl iodide (**4**), prepared in situ from **3** and KI in CH_3CN , was used as an electrophilic d_n -alkylating reagent (Procedure B). Consequently, d_3 -methylation, d_2 -ethylation, and d_2 -phenethylation of complicated substrates including pharmaceuticals (sulfamethoxazole, theophylline, estradiol, thiamazole, ezetimibe, rosoxacin skeleton, etc.). Additionally, d_2 -bromomethylated reagent **3f** was reacted with a catechol moiety to give 1,2-(d_2 -methylene)dioxybenzene derivative (**5b**).

Moreover, **3** were converted into α -deuterated alkyl halide/amine/azide compounds (Figure 5). 1- d_2 -Phenethyl bromide (**6**) with an excellent D contents was prepared from **3c** and KBr (Figure 5-1). 1- d_2 -Phenethylamine (**7**) was obtained through the Gabriel amine synthesis by coupling of potassium phthalimide with **3c** and a subsequent reaction using hydrazine (Figure 5-2). Furthermore, **7** underwent condensation with flurbiprofen to afford the amide product (**8**) without loss of D contents (Figure 5-3). The reaction of **3d** with NaN_3 produced the azido product (**9**), which subsequently underwent Huisgen cyclization with *O*-propargyl triethylene glycol to give a 2-(4-methoxyphenyl)(1- d_2 -ethyl)-substituted triazole derivative (**10**; Figure 5-4).

We performed a deuterium KIE study, relating to metabolic stability using 7-(d_2 -ethoxy)flavone (d_2 -**12**), which was prepared from 7-hydroxyflavone (**11**) and **3b** according to Procedure A (Figure 4-II) as a model antioxidant compound (Figure 6-1). The residual ratios of d_2 -**12** and the hydrogen form (7-ethoxyflavone (**12**)) in the liver microsomal metabolism study revealed a significant effect of deuterium incorporation (Figure 6-A). Additionally, the plasma concentration of d_2 -**12** after oral administration to rats was higher than that of **12** (Figure 6-B). This result indicated that both the C_{max} value and AUC were improved by deuterium KIE (parallel artificial membrane permeability assays showed that there were no significant differences in the membrane permeabilities of d_2 -**12** and **12**).




Figure 5. Further transformation of d_n -alkyl diphenylsulfonium salt reagents. EDC; 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide Hydrochloride, DMAP; 4-dimethylaminopyridine.




Figure 6. Synthesis of 7-(d_2 -ethoxy)flavone and KIE study. C_{max} ; maximum plasma concentration, AUC; area under curve

This concept is the first report on deuterium KIE using a deuterated ethyl moiety. Our strategy is regarded as an innovative drug discovery strategy.^[30,31]

Conclusions and Outlook

The importance of introducing deuterium atoms into drug skeletons for drug discovery has recently been recognized worldwide. However, site-selective deuteration with limited deuterium atoms remains a synthetic hurdle. H/D exchange reactions are powerful and straightforward tools, and using D_2O as an abundant and inexpensive deuterium source is ideal. However, the site selectivity and D contents of the deuterated positions are generally problematic. We successfully established a novel concept to diversify deuterium drug discovery using d_n -alkylation reagents (d_n -alkyl diphenylsulfonium salt) with excellent D contents and perfect site selectivity, which were easily prepared by the H/D exchange reaction of the corresponding hydrogen form using D_2O . Further improvements in diversification will continue to be investigated in our laboratory. This novel synthesis method is expected to contribute to the discovery of deuterium drugs in the future.

Author Contributions

R.O. and K.B. equally contributed to arrange the contents.

Acknowledgements

This study was supported by JSPS KAKENHI Grant Number JP23KJ1515 (for K.B.), JST SPRING Grant Number JPMJSP2138 (for K.B.), JSPS (MEXT grant in aid for transformative research areas (B) Deuterium Science) KAKENHI Grant Number 20H05738 (for Y.S.), Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number 23ama121054 (for Y.S.), Takeda Science Foundation (for Y.S.) and the Mochida Memorial Foundation for Medical and Pharmaceutical Research (for Y.S.).

Conflict of Interests

The authors declare no conflict of interest.

Keywords: Deuteration · Alkylation · Sulfonium salt · Heavy drugs · Kinetic isotope effect

- [1] Recent selected reviews, see; a) F. P. Guengerich, *J. Labelled Compd. Radiopharm.* **2013**, *56* 428–431; b) T. G. Gant, *J. Med. Chem.* **2014**, *57*, 3595–3611; c) M. Dean, V. W. Sung, *Drug Des. Dev. Ther.* **2018**, *12*, 313–319; d) T. Pirali, M. Serafini, S. Cargnin, A. A. Genazzani, *J. Med. Chem.* **2019**, *62*, 5276–5297; e) R. D. Jansen-van Vuuren, L. Jedlovčnik, J. Košmrlj, T. E. Massey, V. Deraud, *ACS Omega* **2022**, *7*, 41840–41858; f) I. D'Acquarica, I. Agrinat, *ACS Pharmacol. Transl. Sci.* **2023**, *6*, 201–219; g) R. Roskoski Jr, *Pharmacol. Res.* **2023**, *189*, 10664; h) R. M. C. D. Martino, B. Maxwell, T. Pirali, *Nat. Rev. Drug Discovery* **2023**, *22*, 562–584; i) X.-L. Xu, W. Zhang, G.-W. Rao, *Curr. Med. Chem.* **2023**, *30*, 4096–4129.
- [2] Recent selected reviews, see; a) K. Dodo, K. Fujita, M. Sodeoka, *J. Am. Chem. Soc.* **2022**, *144*, 19651–19667; b) S. Benson, F. Moliner, W. Tipping, M. Vendrell, *Angew. Chem. Int. Ed.* **2022**, e202204788; c) S. Egoshi, K. Dodo, M. Sodeoka, *Curr. Opin. Chem. Biol.* **2022**, *70*, 102181.
- [3] Recent selected reviews, see; a) J. C. M. Low, A. J. Wright, F. Hesse, J. Cao, K. M. Brindle, *Prog. Nucl. Magn. Reson. Spectrosc.* **2023**, *134–135*, 39–51; b) J. Wan, Y. Guo, H. Chen, P. Sun, X. Zhang, T. Ye, L. Li, F. Pan, L. Yang, *Front. Oncol.* **2023**, *13*, 1285209; c) M. Straathof, A. E. Meerwaldt, H. M. De Feyter, R. A. de Graaf, R. M. Dijkhuizen, *Neuroscience* **2021**, *474*, 94–99; d) I. Polvoy, H. Qin, R. R. Flavell, J. Gordon, P. Viswanath, R. Sriram, M. A. Ohliger, D. M. Wilson, *Metabolites* **2021**, *11*, 570.
- [4] Recent selected reviews, see; a) A. Damont, A. Legrand, C. Cao, F. Fenaillé, J.-C. Tabet, *Mass Spectrom. Rev.* **2023**, *42*, 1300–1331; b) W. Javed, D. Griffiths, A. Politis, *Essays Biochem.* **2023**, *67*, 187–200.
- [5] J. Atzrodt, V. Deraud, W. J. Kerr, M. Reid, *Angew. Chem. Int. Ed.* **2018**, *57*, 1758–1784.
- [6] S. Kopf, F. Bourriquen, W. Li, H. Neumann, K. Junge, M. Beller, *Chem. Rev.* **2022**, *122*, 6634–6718.
- [7] M. Pohjoispää, K. Wähälä, *J. Agric. Food Chem.* **2015**, *63*, 7595–7605.
- [8] Aaron Sattler, *ACS Catal.* **2018**, *8*, 2296–2312.
- [9] J. Atzrodt, V. Deraud, W. J. Kerr, Marc Reid, *Angew. Chem. Int. Ed.* **2018**, *57*, 3022–3047.
- [10] Y. Sawama, K. Park T Yamada, H. Sajiki, *Chem. Pharm. Bull.* **2018**, *66*, 21–28.
- [11] H. Yang, D. Hesk, *J. Labelled Compd. Radiopharm.* **2020**, *63*, 296–307.
- [12] A. Michelotta, M. Roche, *Synthesis* **2019**, *51*, 1319–1328.
- [13] P. Ranjan, S. Pillitteri, E. V. Van der Eycken, U. K. Sharma, *Green Chem.* **2020**, *22*, 7725–7736.
- [14] M. Valero, V. Deraud, *J. Labelled Compd. Radiopharm.* **2020**, *63*, 266–280.
- [15] D. Hesk, *J. Labelled Compd. Radiopharm.* **2020**, *63*, 247–265.
- [16] M. Lepron, M. Daniel-Bertrand, G. Mencia, B. Chaudret, S. Feuillastre, G. Pieters, *Acc. Chem. Res.* **2021**, *54*, 1465–1480.
- [17] R. Zhou, L. Ma, X. Yanga, J. Cao, *Org. Chem. Front.* **2021**, *8*, 426–444.
- [18] P. Grocholska, R. Bączor, *Molecules* **2021**, *26*, 2989.
- [19] X. Yang, H. Ben, A. J. Ragauskas, *Asian J. Org. Chem.* **2021**, *10*, 2473–2485.
- [20] N. Li, Y. Li, X. Wu, C. Zhua, J. Xie, *Chem. Soc. Rev.* **2022**, *51*, 6291–6306.

- [21] D. Sharma, R. Chatterjee, V. Dhayalan, R. Dhanusuraman, R. Dandela, *Chem. Asian J.* **2022**, *17*, e202200485.
- [22] T. Shinada, A. Nakayama, H. Okamura, Yoko Yasuno, *Bull. Chem. Soc. Jpn.* **2022**, *95*, 1461–1473.
- [23] G. Prakash, N. Paul, G. A. Oliver, D. B. Werz, D. Maiti, *Chem. Soc. Rev.* **2022**, *51*, 3123–3163.
- [24] A. Tortajada, E. Hevia, *Catal. Sci. Technol.* **2023**, *13*, 4919–4925.
- [25] H. Li, M. Shabbir, W. Li, A. Lei, *Chin. J. Chem.* **2023**, *41*, 10.1002/cjoc.202300570.
- [26] A. Sib, V. Derdau, *Synlett* **2024**, *56*, DOI: 10.1055/a-2222-1667.
- [27] M. Wang, Y. Zhao, Y. Zhao, Z. Shi, *Sci. Adv.* **2020**, *6*, eaba0946.
- [28] J. Chen, S. Liu, S. Su, R. Fan, R. Zhang, W. Meng, J. Tan, *Sci. Adv.* **2023**, *9*, eadi1370.
- [29] K. Ban, K. Imai, S. Oyama, J. Tokunaga, Y. Ikeda, H. Uchiyama, K. Kadota, Y. Tozuka, S. Akai, Y. Sawama, *Angew. Chem. Int. Ed.* **2023**, e202311058.
- [30] D. Trauner, A. Sailer, *Synfacts* 01122023, 19(12), 1264.
- [31] J. A. Schwindeman, D. S. B. Daniels, A. Kosanovich, C. B. Kelly, T. Kwok, S. Guizzetti, E. Dauncey, A. Q. Ansel, J. M. MacDougall, J. Knight, *Org. Process Res. Dev.* **2023**, *27*, 2197–2210.


Manuscript received: March 18, 2024

Revised manuscript received: May 11, 2024

Accepted manuscript online: May 13, 2024

Version of record online: ■■, ■■

CONCEPT



Recently, deuterated drugs have been highlighted as a new modality, and H/D exchange reactions are powerful and straightforward synthetic tools. We have successfully established a novel concept to diversify deuterium drug discovery using d_n -alkylation

reagents (d_n -alkyl diphenylsulfonium salts) with excellent D contents and perfect site selectivity, which are readily prepared by the H/D exchange reaction of the corresponding hydrogen form using inexpensive D_2O .

R. Ogasahara, K. Ban, M. Mae,
Prof. Dr. S. Akai, Dr. Y. Sawama*

1 – 7

Deuterated Alkyl Sulfonium Salt Reagents; Importance of H/D Exchange Methods in Drug Discovery